長江健康(002435.SZ)：二級子公司華信製藥失控
格隆匯4月6日丨長江健康(002435.SZ)公佈，公司年報審計工作組於2020年3月16日進駐公司二級子公司山東華信製藥集團股份有限公司(“華信製藥”)開展2019年度審計相關工作。審計工作組在開展工作期間多次無端受到華信製藥董事馬俊華(兼總經理)以及劉瑞環組織人員的圍攻圍堵，阻撓審計，甚至發生危及工作組成員人身安全的事宜。公司層面雖多次和阻擾人員積極協商溝通，甚至菏澤市高新區領導也多次出面協調，但均無效果。目前審計程序、審計工作無法正常推進，公司事實上已對華信製藥失去控制。
華信製藥基本情況：
2018年7月，公司通過全資子公司長江潤髮張家港保税區醫藥投資有限公司(“長江醫藥”)與華信製藥原股東馬俊華、劉瑞環、王萍、上海和儒投資管理中心(有限合夥)簽署《山東華信製藥集團股份有限公司股份轉讓協議》，以現金人民幣9.3億元收購華信製藥60%股權。
按照《股權轉讓協議》的約定，華信製藥新設董事會有5名成員，其中長江醫藥向華信製藥委派3名董事，馬俊華、劉瑞環同為董事，董事會聘任馬俊華為華信製藥總經理，負責華信製藥的日常運營，長江醫藥向華信製藥派駐副總經理、財務總監各一名，同時負責保管華信製藥的營業執照、公章、合同章、法人章及網銀U盾。
按照《股權轉讓協議》約定，馬俊華、劉瑞環承諾2018年、2019年、2020年華信製藥實現的淨利潤(該淨利潤指的是華信製藥經具有證券期貨從業資格的會計師事務所審定的扣除非經常性損益後的淨利潤)不低於人民幣1億元、1.4億元和1.96億元；公司按照華信製藥實際完成的業績情況分三期向甲方馬俊華支付其應得的剩餘50%股份轉讓價款；同時，若未能完成業績承諾，馬俊華及劉瑞環須對公司進行業績補償。
截止目前，公司已支付股權轉讓價款53948.1175萬元；2018年股權轉讓款餘11017.2958萬元未支付，馬俊華對此已提出仲裁請求，目前該仲裁案件尚未開庭審理。
公司將委託律師事務所向北京仲裁委員會提起仲裁，要求馬俊華、劉瑞環嚴格履行《股權轉讓協議》約定，並接受具有證券期貨從業資格的會計師事務所進行專項審計。
按照《公司法》、《證券法》的要求，落實華信製藥治理規章制度，積極通過其他法律手段維護上市公司及全體投資者的合法權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
